Clinical trials: Liver Cirrhosis, completed
Liver Cancer, Liver Cirrhoses
Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis
This study compares gadolinium contrast-enhanced Abbreviated MRI (AMRI) to standard ultrasound for Hepatocellular Carcinoma (HCC) screening and surveillance in subjects with liver cirrhosis.
- Conditions
- Liver Cancer, Liver Cirrhoses, Liver Carcinoma
- Trial name
- NCT04288323
- Testing
- Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- University of California, San Diego
NASH - Nonalcoholic Steatohepatitis
A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in cirrhotic subjects with biopsy-proven F4 compensated NASH.
- Trial name
- NCT05039450
- Testing
- EFX
- Where
- 49 sites in United States, Mexico and 1 more
- Volunteers
- 213 people
- Sponsor
- Akero Therapeutics, Inc
Cirrhosis
Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome
Study to test the effect of the drug "L-ornithine.L-aspertate" (LOLA) on microorganisms in the digestive tract in patients with liver cirrhosis (damage of the liver due to liver disease)
- Trial name
- LOLAbiome (NCT05737030)
- Testing
- L-ornithine L-aspartate
- Where
- Austria
- Volunteers
- 52 people
- Sponsor
- Medical University of Graz
Fatty Liver, Liver Fibrosis
Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis
The purpose of this interventional study is to evaluate the efficacy and tolerability of docosahexaenoic acid (DHA), Vitamin E and Choline in children or adolescents with well-characterized and liver biopsy confirmed nonalcoholic…
- Conditions
- Fatty Liver, Liver Fibrosis, Obesity, Metabolic Syndrome
- Trial name
- NCT01934777
- Testing
- Docosahexaenoic Acid plus Vitamin E plus choline
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Thrombocytopenia Related to Chronic Liver Disease, Anticoagulation Treatment
Safety of Anticoagulation Therapy in Cirrhotic Patients With PVT and Severe Thrombocytopenia
Severe thrombocytopenia (platelet count ≤ 50 × 10^9/L) can significantly increase the risk of bleeding. Safety of Anticoagulation (AC) therapy in cirrhotic patients with portal vein thrombosis (PVT) and severe thrombocytopenia is…
- Conditions
- Thrombocytopenia Related to Chronic Liver Disease, Anticoagulation Treatment, Safety, Portal Vein Thrombosis
- Trial name
- AC in PVT (NCT07885969)
- Testing
- Anticoagulation Therapy
- Where
- China
- Volunteers
- 304 people
- Sponsor
- Qilu Hospital of Shandong University
Hyponatremia With Excess Extracellular Fluid Volume, Cirrhosis, Liver
Albumin for Management of Hypervolemic Hyponatremia (AlbuCAT)
resolution of hyponatremia, defined as an increase in serum sodium of more than 5 mEq/L with a final value > 130 mEq/L, maintained for at least 48 consecutive hours during the 10-day treatment period
- Trial name
- AlbuCAT (NCT03941405)
- Testing
- Albumin treatment
- Where
- 3 sites in Spain
- Volunteers
- 52 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Liver Cirrhosis
Systemic Inflammation in Liver Cirrhosis
Investigate systemic inflammation in liver cirrhosis patients
- Trial name
- SILC (NCT04850534)
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Primary Biliary Cholangitis
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)
This study will collect information from patients with Primary Biliary Cholangitis (PBC). PBC is a progressive rare liver disease in which tubes in the liver called bile ducts are damaged.
- Trial name
- NCT07049887
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Ipsen
Advanced Chronic Liver Disease, Healthy Participants
A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine
The purpose of this study is to assess the pharmacokinetics (PK) and safety of AZD2389 when administered alone and in combination with quinidine in healthy participants.
- Trial name
- NCT06974565
- Testing
- AZD2389, Quinidine
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cirrhosis, MASLD
DEFINITION OF THE GENOMIC LANDSCAPE OF MASLD
The Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a leading cause of chronic liver disease globally, with a prevalence exceeding 30% in the population.
- Trial name
- NCT07249112
- Testing
- genetic and somatic variants involved in its progression toward advanced fibrosis and hepatocellular carcinoma
- Where
- Italy
- Volunteers
- 2,880 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
HepatoCellular Carcinoma, Cirrhosis
Mutational Landscape in Hepatocellular Carcinoma
The MUTHEC project aims to describe the mutational and transcriptomic landscape of HCC treated by curative treatments (resection, radio frequency ablation, transplantation) as well as advanced HCC together with the analysis of…
- Trial name
- MUTHEC (NCT03071458)
- Where
- France
- Volunteers
- 808 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Muscle Cramp, Cirrhosis
Effect of Branched-chain Amino Acids (BCAA) to Muscle Cramps in Patients With Cirrhosis
The goal of this randomized controlled trial is to compare the efficacy and safety of branched-chain amino acids (BCAA) versus placebo for treating muscle cramps in cirrhotic patients.
- Conditions
- Muscle Cramp, Cirrhosis, Quality of Life
- Trial name
- NCT05724485
- Testing
- Branched-chain Amino Acid
- Where
- Thailand
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Liver Cirrhosis, Portal Hypertension
Accuracy of Magnetically Maneuvered Capsule Endoscopy for Detection of EGV in Patients With Cirrhosis
This is a diagnostic accuracy study. Eligible individuals will be enrolled and asked to undergo ds-MCE and EGD examinations. EGD is the reference standard against which ds-MCE is compared, and it will be performed within 48 hours…
- Conditions
- Liver Cirrhosis, Portal Hypertension, Esophageal Varices, Gastric Varix
- Trial name
- NCT03748563
- Testing
- ds-MCE and EGD
- Where
- 14 sites in China
- Volunteers
- 607 people
- Sponsor
- Changhai Hospital
Liver Cirrhosis, Alcoholic
Efficacy of Baclofen in the Treatment of Alcohol Addiction
Intervention to achieve alcohol abstinence represents the most effective treatment for alcoholic patients with liver cirrhosis. However no trials have evaluated the efficacy of anti-craving drugs in these patients because of the…
- Trial name
- NCT00525252
- Testing
- Baclofen
- Volunteers
- 86 people
- Sponsor
- Catholic University of the Sacred Heart
Primary Biliary Cholangitis
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
The participants in this study will have confirmed PBC with inadequate response or intolerance to Ursodeoxycholic acid (UDCA), which is a medication used in the management and treatment of cholestatic liver disease.
- Trial name
- ELSPIRE (NCT06383403)
- Testing
- Elafibranor
- Where
- 60 sites in United States, Czechia and 8 more
- Volunteers
- 92 people
- Sponsor
- Ipsen
Cirrhoses, Liver
Simvastatin Plus Rifaximin in Decompensated Cirrhosis
The main purpose of this study is to investigate whether the combination of two different drugs, simvastatin and rifaximin, is safe in the treatment of patients with decompensated cirrhosis.
- Trial name
- LIVERHOPE (NCT03150459)
- Testing
- Simvastatin 20 mg, Simvastatin 40mg, Rifaximin 400 mg
- Where
- 9 sites in France, Germany and 4 more
- Volunteers
- 44 people
- Sponsor
- Judit Pich
Drug Resistance, Multiple, Bacterial Infections
Prediction of Multidrug-resistant Bacterial Infection in Patients with Cirrhosis
The aim of this study is to identify predictive factors of infections caused by multidrug-resistant organisms in patients with cirrhosis and to develop and validate (internally and externally) a predictive model that might be…
- Conditions
- Drug Resistance, Multiple, Bacterial Infections, Liver Cirrhosis
- Trial name
- NCT05641025
- Where
- Argentina
- Volunteers
- 1,774 people
- Sponsor
- Hospital Italiano de Buenos Aires
Chronic Liver Disease and Cirrhosis
Immunological Measurement of Aspartate/Alanine Aminotransferase
Previous reports have suggested that ALT-immunoglobulin complex was increased according to the severity of the liver disease, and high concentration of mAST and this might indicate a severely damaged liver.
- Trial name
- NCT03562585
- Testing
- with sandwich ELISA immunoassay with fluorescence labeled monoclonal antibodies
- Volunteers
- 219 people
- Sponsor
- Chuncheon Sacred Heart Hospital
Primary Biliary Cirrhosis
Effect of Obeticholic Acid on Transport of Bile Acids in PBC Examined by 11C-cholyl-sarcosine PET/CT
This is an investigator-initiated, double-blind crossover study on the mechanism of OCA treatment of patients with PBC. Hypothesis and significance The investigators will test the hypothesis that OCA administration to patients…
- Trial name
- NCT03253276
- Testing
- Obeticholic acid
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- University of Aarhus
Hepatitis C Virus Infection
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) and SOF/VEL FDC and ribavirin (RBV) for 12 weeks in participants with…
- Trial name
- NCT02781558
- Testing
- SOF/VEL, RBV
- Where
- 28 sites in Spain
- Volunteers
- 204 people
- Sponsor
- Gilead Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.